See more : Delta Plus Group (DLTA.PA) Income Statement Analysis – Financial Results
Complete financial analysis of Novozymes A/S (NVZMY) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Novozymes A/S, a leading company in the Chemicals – Specialty industry within the Basic Materials sector.
- Advanced Emissions Solutions, Inc. (ADES) Income Statement Analysis – Financial Results
- Biofrontera AG (B8F.DE) Income Statement Analysis – Financial Results
- Elvalhalcor Hellenic Copper and Aluminium Industry S.A. (ELHA.AT) Income Statement Analysis – Financial Results
- Diablo Resources Limited (DBORF) Income Statement Analysis – Financial Results
- Vermilion Energy Inc. (VET.TO) Income Statement Analysis – Financial Results
Novozymes A/S (NVZMY)
About Novozymes A/S
Novozymes A/S produces and sells industrial enzymes, microorganisms, and probiotics in Europe, the Middle East, Africa, North America, the Asia Pacific, and Latin America. The company offers baking, beverages, dairy, starch, and protein solutions for the food and beverage industry; laundry, dishwashing, and professional cleaning solutions for the household care industry; agriculture solutions, including crop production, and animal health and nutrition solutions; bioyield and biocontrol solutions for crops; and grain and technical processing solutions, as well as bio energy solutions for liquefaction, saccharifaction, fermentation, fiber conversion, and biomass conversion. It also provides textile solutions, such as biopreparation, biopolishing, bleach clean-up, denim abrasion and finishing, and desizing solutions. In addition, the company offers solutions for pulp & paper, including fiber modification, bleach boosting, deposit control, starch modification, and deinking; leather solutions comprising acid bating, area expansion, bating, degreasing, soaking, and unhairing and liming; and water and waste management solutions, which consist of bioaugmentation, biogas, and sludge management. Further, it provides pharmaceutical solutions, including lipases, immobilized lipases, and proteases for biocatalysis, as well as rTrypsin for cell culture; and human health and protein solutions. The company was founded in 1925 and is headquartered in Bagsvaerd, Denmark.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 17.90B | 17.55B | 14.95B | 14.01B | 14.37B | 14.39B | 14.53B | 14.14B | 14.00B | 12.46B | 11.75B | 11.23B | 10.51B | 9.72B | 8.45B | 8.15B | 7.44B | 6.80B | 6.28B | 6.02B | 5.80B | 5.64B |
| Cost of Revenue | 8.18B | 7.98B | 6.33B | 6.16B | 6.42B | 6.14B | 6.12B | 6.02B | 5.87B | 5.31B | 5.03B | 4.81B | 4.60B | 4.31B | 3.75B | 3.79B | 3.49B | 3.15B | 2.94B | 2.85B | 2.80B | 2.73B |
| Gross Profit | 9.72B | 9.58B | 8.62B | 7.85B | 7.95B | 8.26B | 8.41B | 8.13B | 8.13B | 7.15B | 6.72B | 6.42B | 5.91B | 5.41B | 4.70B | 4.36B | 3.95B | 3.66B | 3.35B | 3.18B | 3.00B | 2.91B |
| Gross Profit Ratio | 54.32% | 54.56% | 57.68% | 56.04% | 55.34% | 57.37% | 57.90% | 57.46% | 58.06% | 57.38% | 57.18% | 57.17% | 56.21% | 55.66% | 55.63% | 53.51% | 53.09% | 53.73% | 53.26% | 52.77% | 51.77% | 51.54% |
| Research & Development | 2.02B | 2.00B | 2.01B | 1.94B | 1.97B | 1.87B | 1.91B | 1.87B | 1.90B | 1.84B | 1.53B | 1.53B | 1.46B | 1.36B | 1.21B | 1.10B | 995.00M | 880.00M | 793.00M | 775.00M | 749.00M | 713.00M |
| General & Administrative | 959.00M | 952.00M | 859.00M | 739.00M | 838.00M | 792.00M | 831.00M | 810.00M | 876.00M | 857.00M | 824.00M | 808.00M | 778.00M | 762.00M | 751.00M | 745.00M | 675.00M | 650.00M | 632.00M | 595.00M | 587.00M | 575.00M |
| Selling & Marketing | 2.37B | 2.27B | 1.94B | 1.58B | 1.63B | 1.57B | 1.62B | 1.62B | 1.57B | 1.41B | 1.48B | 1.42B | 1.38B | 1.24B | 1.12B | 1.06B | 921.00M | 844.00M | 748.00M | 750.00M | 730.00M | 729.00M |
| SG&A | 3.32B | 3.22B | 2.80B | 2.32B | 2.47B | 2.36B | 2.45B | 2.43B | 2.45B | 2.26B | 2.30B | 2.23B | 2.15B | 2.00B | 1.87B | 1.81B | 1.60B | 1.49B | 1.38B | 1.35B | 1.32B | 1.30B |
| Other Expenses | 405.00M | -75.00M | -66.00M | -14.00M | -26.00M | -43.00M | -63.00M | -117.00M | -98.00M | -102.00M | -13.00M | 9.00M | -50.00M | -69.00M | -64.00M | -47.00M | -123.00M | -59.00M | -34.00M | -31.00M | -44.00M | -56.00M |
| Operating Expenses | 5.75B | 5.15B | 4.74B | 4.24B | 4.41B | 4.19B | 4.30B | 4.18B | 4.25B | 4.00B | 3.82B | 3.68B | 3.57B | 3.30B | 3.01B | 2.86B | 2.47B | 2.32B | 2.14B | 2.09B | 2.02B | 1.96B |
| Cost & Expenses | 13.92B | 13.13B | 11.07B | 10.40B | 10.83B | 10.32B | 10.42B | 10.20B | 10.12B | 9.31B | 8.85B | 8.49B | 8.17B | 7.61B | 6.76B | 6.64B | 5.96B | 5.46B | 5.08B | 4.93B | 4.82B | 4.70B |
| Interest Income | 24.00M | 18.00M | 18.00M | 10.00M | 90.00M | 10.00M | 7.00M | 5.00M | 4.00M | 9.00M | 5.00M | 13.00M | 208.00M | 113.00M | 153.00M | 263.00M | 130.00M | 134.00M | 76.00M | 89.00M | 223.00M | 131.00M |
| Interest Expense | 173.00M | 102.00M | 102.00M | 63.00M | 86.00M | 13.00M | 27.00M | 31.00M | 31.00M | 58.00M | 66.00M | 74.00M | 133.00M | 107.00M | 220.00M | 348.00M | 226.00M | 256.00M | 132.00M | 98.00M | 190.00M | 178.00M |
| Depreciation & Amortization | 1.39B | 1.46B | 1.37B | 1.23B | 1.17B | 1.01B | 1.04B | 974.00M | 953.00M | 866.00M | 738.00M | 703.00M | 208.00M | 113.00M | 564.00M | 556.00M | 490.00M | 469.00M | 462.00M | 519.00M | 523.00M | 532.00M |
| EBITDA | 5.47B | 6.12B | 5.20B | 4.85B | 5.07B | 5.04B | 5.19B | 4.89B | 4.77B | 4.20B | 3.56B | 3.36B | 2.55B | 2.23B | 2.41B | 2.32B | 2.10B | 1.94B | 1.74B | 1.67B | 1.73B | 1.61B |
| EBITDA Ratio | 30.57% | 34.60% | 34.76% | 34.26% | 32.84% | 34.60% | 35.74% | 34.36% | 34.08% | 31.73% | 29.86% | 29.92% | 24.24% | 22.93% | 28.47% | 28.52% | 28.25% | 10.92% | 27.77% | 28.19% | 29.78% | 28.54% |
| Operating Income | 3.98B | 4.63B | 4.01B | 3.65B | 4.04B | 4.07B | 4.05B | 3.95B | 3.88B | 3.38B | 2.90B | 2.75B | 2.34B | 2.12B | 1.69B | 1.50B | 1.48B | 1.34B | 1.21B | 1.09B | 982.00M | 947.00M |
| Operating Income Ratio | 22.21% | 26.37% | 26.80% | 26.06% | 28.10% | 28.28% | 27.85% | 27.90% | 27.74% | 27.16% | 24.70% | 24.43% | 22.26% | 21.77% | 19.98% | 18.46% | 19.91% | 19.70% | 19.20% | 18.09% | 16.92% | 16.78% |
| Total Other Income/Expenses | -67.00M | -73.00M | -83.00M | -131.00M | -240.00M | -134.00M | -171.00M | -65.00M | -263.00M | -105.00M | -142.00M | -161.00M | 75.00M | 6.00M | -67.00M | -85.00M | -96.00M | -122.00M | -56.00M | -33.00M | 33.00M | -47.00M |
| Income Before Tax | 3.91B | 4.56B | 3.92B | 3.52B | 3.80B | 3.94B | 3.88B | 3.88B | 3.62B | 3.28B | 2.76B | 2.58B | 2.42B | 2.12B | 1.62B | 1.42B | 1.39B | 18.00M | 1.15B | 1.08B | 1.02B | 900.00M |
| Income Before Tax Ratio | 21.84% | 25.96% | 26.25% | 25.13% | 26.43% | 27.35% | 26.67% | 27.44% | 25.86% | 26.32% | 23.49% | 23.00% | 22.98% | 21.83% | 19.19% | 17.42% | 18.62% | 0.26% | 18.31% | 17.94% | 17.49% | 15.95% |
| Income Tax Expense | 870.00M | 870.00M | 779.00M | 695.00M | 644.00M | 709.00M | 756.00M | 831.00M | 796.00M | 754.00M | 558.00M | 568.00M | 587.00M | 509.00M | 427.00M | 357.00M | 343.00M | -307.00M | 289.00M | 288.00M | 280.00M | 253.00M |
| Net Income | 3.02B | 3.68B | 3.15B | 2.83B | 3.15B | 3.23B | 3.12B | 3.05B | 2.82B | 2.53B | 2.20B | 2.02B | 1.83B | 1.61B | 1.19B | 1.06B | 1.04B | 911.00M | 861.00M | 793.00M | 735.00M | 647.00M |
| Net Income Ratio | 16.89% | 20.94% | 21.04% | 20.16% | 21.94% | 22.42% | 21.46% | 21.57% | 20.16% | 20.27% | 18.73% | 17.94% | 17.39% | 16.60% | 14.13% | 13.04% | 14.01% | 13.39% | 13.71% | 13.16% | 12.67% | 11.47% |
| EPS | 10.88 | 13.29 | 11.32 | 10.07 | 11.06 | 11.11 | 10.56 | 10.15 | 9.23 | 8.10 | 7.01 | 6.42 | 5.80 | 5.15 | 3.85 | 3.43 | 3.37 | 2.90 | 2.63 | 2.32 | 2.09 | 1.79 |
| EPS Diluted | 10.88 | 13.19 | 11.23 | 10.02 | 11.01 | 11.03 | 10.49 | 10.06 | 9.12 | 8.02 | 6.93 | 6.33 | 5.71 | 5.05 | 3.79 | 3.37 | 3.28 | 2.82 | 2.57 | 2.27 | 2.07 | 1.78 |
| Weighted Avg Shares Out | 277.94M | 276.64M | 277.92M | 280.43M | 285.11M | 290.42M | 295.34M | 300.47M | 306.00M | 311.90M | 313.76M | 313.98M | 315.16M | 313.18M | 310.27M | 309.35M | 309.57M | 314.37M | 327.31M | 341.38M | 352.30M | 361.68M |
| Weighted Avg Shares Out (Dil) | 277.87M | 278.73M | 280.23M | 282.02M | 286.55M | 292.36M | 297.20M | 303.12M | 309.37M | 315.08M | 317.41M | 318.28M | 319.96M | 319.38M | 315.36M | 315.01M | 318.12M | 322.52M | 335.34M | 349.25M | 354.33M | 362.80M |
Completion of the combination between Novozymes and Chr. Hansen
The combination of Novozymes and Chr. Hansen is now successfully completed, creating Novonesis – a leading global biosolutions partner
Completion of the combination between Novozymes and Chr. Hansen
All necessary regulatory approvals have been obtained for the combination of Novozymes and Chr. Hansen
All necessary regulatory approvals have been obtained for the combination of Novozymes and Chr. Hansen
AXTA or NVZMY: Which Is the Better Value Stock Right Now?
Update on the merger approval process for the combination of Novozymes and Chr. Hansen: South Korean merger approval granted
Novozymes' updated financial calendar
Novozymes and Chr. Hansen announce name of future combined company; Novonesis
Update on the merger approval process for the combination of Novozymes and Chr. Hansen: Conditional competition clearance from the European Commission obtained
Source: https://incomestatements.info
Category: Stock Reports